DTU Publications 2020-2023
2023
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Morrow LM. et al, (2024), J Diabetes, 16
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
Timing of SGLT2i initiation after acute myocardial infarction.
von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis.
Taylor R. et al, (2023), Clin Sci (Lond)
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
Regan JA. et al, (2023), JCI Insight
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Maddaloni E. et al, (2023), Diabetes Metab Res Rev
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Othonos N. et al, (2023), Nat Commun, 14
Teplizumab approval for type 1 diabetes in the USA.
Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials
Maddaloni E. et al, (2023), Diabetes, Obesity and Metabolism
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Green JB. et al, (2023), Diabetes, Obesity and Metabolism
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Shields BM. et al, (2022), Nat Med
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Shields BM. et al, (2022), Nat Med
What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
Kc S. et al, (2023), Int J Health Policy Manag, 12
2022
A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.
Williams SA. et al, (2022), Sci Transl Med, 14
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
Dennis JM. et al, (2022), Lancet Digit Health, 4, e873 - e883
A brief history of the UK Prospective Diabetes Study
Holman RR., (2022), BRITISH JOURNAL OF DIABETES, 22, S32 - S35
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842
Empagliflozin in acute Myocardial Infarction: the EMMY trial.
von Lewinski D. et al, (2022), Eur Heart J
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events.
Regan JA. et al, (2022), Sci Rep, 12
Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study.
Xu S. et al, (2022), Cardiovasc Diabetol, 21
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654
Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial.
Leal J. et al, (2022), J Diabetes, 14, 455 - 464
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Davis TME. et al, (2022), Cardiovasc Diabetol, 21
Validation of the WATCH-DM and TRS-HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis.
Segar MW. et al, (2022), J Am Heart Assoc, 11
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.
Becker F. et al, (2022), Diabetes Res Clin Pract, 183
The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized trials
Preiss D. et al, (2022), DIABETES RESEARCH AND CLINICAL PRACTICE, 186
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
Sharma A. et al, (2022), Diabetes Care, 45, 204 - 212
2021
The STEP 1 trial for weight loss: a step change in treating obesity?
Adler AI., (2021), Nat Med, 27, 589 - 590
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
Samsky MD. et al, (2021), Atherosclerosis, 338, 1 - 6
Nintedanib for treating progressive fibrosing interstitial lung diseases.
Adler AI. et al, (2021), Lancet Respir Med, 9, e116 - e117
Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).
Leal J. et al, (2021), Diabet Med, 38
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88.
Lind M. et al, (2021), Diabetes Care
Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.
Weissler EH. et al, (2021), Diabet Med, 38
Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance.
Xu S. et al, (2021), J Diabetes, 13, 817 - 826
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
Rahimi K. et al, (2021), The Lancet, 398, 1053 - 1064
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus
Barbery CE. et al, (2021), American Heart Journal, 239, 59 - 63
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Hundertmark MJ. et al, (2021), ESC Heart Fail, 8, 2580 - 2590
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.
Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884
Neck circumference and waist circumference associated with cardiovascular events in type 2 diabetes (Beijing Community Diabetes Study 23).
Yang G-R. et al, (2021), Sci Rep, 11
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
Clegg LE. et al, (2021), Diabetes Obes Metab, 23, 1101 - 1110
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Copland E. et al, (2021), Lancet Oncol, 22, 558 - 570
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Adler AI. et al, (2021), Lancet Diabetes Endocrinol, 9, 261 - 263
NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura.
Hughes M. et al, (2021), Lancet Haematol, 8, e14 - e15
Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.
Adler AI. and Latimer NR., (2021), JAMA, 325, 2110 - 2111
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration None., (2021), Lancet, 397, 1625 - 1636
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.
Blood Pressure Lowering Treatment Trialists' Collaboration None., (2014), Lancet, 384, 591 - 598
2020
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis.
Juraschek SP. et al, (2021), Ann Intern Med, 174, 58 - 68
TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.
Angwin C. et al, (2020), BMJ Open, 10
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data.
Leal J. et al, (2020), Diabetes Care, 43, 2485 - 2492
Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
Gerstein HC. et al, (2020), Diabetes Care, 43, 2242 - 2247
Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
Agbaje OF. et al, (2020), Diabetes Res Clin Pract, 166
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
Baggio LL. et al, (2020), Nat Commun, 11
Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.
Ballav C. et al, (2020), Endocrinol Diabetes Metab, 3
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Coleman RL. et al, (2020), Diabetes Obes Metab, 22, 1151 - 1156
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.
McGovern AP. et al, (2020), BMJ Open Diabetes Res Care, 8
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Chan JCN. et al, (2021), Lancet, 396, 2019 - 2082
Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M. et al, (2020), Diabetes Res Clin Pract, 170
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
van der Aart‐van der Beek AB. et al, (2020), Diabetes, Obesity and Metabolism, 22, 2493 - 2498
Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.
Zhou JJ. et al, (2020), Diabetologia, 63, 2482 - 2485
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
McAlister FA. et al, (2020), Eur J Heart Fail, 22, 2026 - 2034
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: A multicentre retrospective study (CoViDiab II)
Maddaloni E. et al, (2020), Cardiovascular Diabetology, 19
Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning.
Dakin HA. et al, (2020), Value Health, 23, 1340 - 1348
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
Donnelly LA. et al, (2020), Diabetes Care, 43, 2493 - 2499